These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37286407)

  • 21. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
    Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
    Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    de Sévaux JL; Venekamp RP; Lutje V; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD001480. PubMed ID: 33231293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. All-cause pneumonia in children after the introduction of pneumococcal vaccines in the United Kingdom: A population-based study.
    Lau WCY; Bielicki J; Tersigni C; Saxena S; Wong ICK; Sharland M; Hsia Y
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):821-829. PubMed ID: 30993835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R;
    Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
    Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B
    Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumonia in Elderly Australians: Reduction in Presumptive Pneumococcal Hospitalizations but No Change in All-Cause Pneumonia Hospitalizations Following 7-Valent Pneumococcal Conjugate Vaccination.
    Menzies RI; Jardine A; McIntyre PB
    Clin Infect Dis; 2015 Sep; 61(6):927-33. PubMed ID: 26066319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: Time series analyses.
    Jimbo Sotomayor R; Toscano CM; Sánchez Choez X; Vilema Ortíz M; Rivas Condo J; Ghisays G; Haneuse S; Weinberger DM; McGee G; de Oliveira LH
    Vaccine; 2020 Oct; 38(45):7033-7039. PubMed ID: 32981782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012.
    Griffin MR; Mitchel E; Moore MR; Whitney CG; Grijalva CG;
    MMWR Morb Mortal Wkly Rep; 2014 Nov; 63(44):995-8. PubMed ID: 25375070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Pneumococcal Vaccination on Pneumonia Hospitalizations and Related Costs in Ontario: A Population-Based Ecological Study.
    Luca DL; Kwong JC; Chu A; Sander B; O'Reilly R; McGeer AJ; Bloom DE
    Clin Infect Dis; 2018 Feb; 66(4):541-547. PubMed ID: 29029063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of pneumococcal conjugate vaccines on the incidence of pneumonia in hospitalized children after five years of its introduction in Uruguay.
    Hortal M; Estevan M; Meny M; Iraola I; Laurani H
    PLoS One; 2014; 9(6):e98567. PubMed ID: 24905093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2021 Feb; 17(2):517-526. PubMed ID: 32574101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.
    Gönüllü E; Soysal A; Yıldız I; Aydemir G; Tunç T; Karaböcüoğlu M
    Hum Vaccin Immunother; 2020 Oct; 16(10):2504-2508. PubMed ID: 32119602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in the epidemiology and clinical features of acute mastoiditis following the introduction of the pneumococcal conjugate vaccine.
    Cavel O; Tauman R; Simsolo E; Yafit D; Reindorf-Kfir E; Wasserzug O; Unger O; Handzel O; Fishman G; Oestreicher-Kedem Y; DeRowe A
    Int J Pediatr Otorhinolaryngol; 2018 Jan; 104():54-57. PubMed ID: 29287882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
    Regev-Yochay G; Katzir M; Strahilevitz J; Rahav G; Finn T; Miron D; Maor Y; Chazan B; Schindler Y; Dagan R;
    Vaccine; 2017 Apr; 35(18):2449-2456. PubMed ID: 28342668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.